Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Simple urine test may spot kidney trouble early in kids with cancer

NCT ID NCT02822404

Knowledge-focused Sponsor: University Hospital, Toulouse Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a substance called cystatin C, measured in urine and blood, can detect kidney damage from chemotherapy drugs cisplatin and ifosfamide in children. Researchers followed 42 children and compared cystatin C levels to standard kidney tests. The goal was to find a simpler, less burdensome way to monitor kidney health during cancer treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If cystatin C proves reliable, it could offer a simpler, less invasive way to monitor kidney health in children undergoing chemotherapy.
What could go wrong
This is a small, completed observational study. The marker may not be accurate enough to replace current tests, and results may not apply to all children or treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

42 people

The number who actually took part.

Started

Feb 2012

Finished

May 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Up to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Children of 0 to18 years treated with cisplatin and / or ifosfamide in the hematology-oncology unit of Toulouse University Hospital of children regardless to the pathology they have been treated for * Children with more than 4kg * Written informed consent given by both parents or legal representative * Patient covered by a social security agreement Exclusion Criteria: * Impossibility to monitor and follow up the patient until the foreseeable end of the treatment (geographic reasons, etc.) * Contraindication to EDTA clearance performing

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Kidney diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

kidney disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Kidney diseases

Contacts and locations

Locations

  • CHU Toulouse

    Toulouse, 31059, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.